GLP-1 drugs show promise for leg artery disease, new data suggests

A new wave of research suggests that popular GLP-1 drugs, originally designed for diabetes and weight loss, may also help patients with peripheral artery disease (PAD). PAD narrows arteries in the legs, often causing severe pain while walking and increasing the risk of amputation. Early signs from ongoing studies indicate that these medicines could improve blood flow and reduce inflammation in affected limbs. While the findings are still preliminary, they add to a growing list of potential uses for the blockbuster drug class. Separately, biotech firm BridgeBio announced a major financial deal, securing over $1 billion in funding to advance its pipeline. The company is focusing on genetic diseases, including a treatment for a rare form of heart condition. These developments highlight a busy period for the biotech sector, where established drugs find new applications and newer companies secure massive investments.